Denikitug  (Synonyms: GS-1811; JTX-1811)

Denikitug (GS-1811; JTX-1811) is a humanized monoclonal antibody against CCR8 receptor with a K_D of 16.8 pM. Denikitug specifically binds to human CCR8, inhibits CCL1-induced downstream CCR8 signaling. Denikitug selectively depletes cells expressing CCR8 via antibody-dependent cellular cytotoxicity (ADCC). Denikitug promotes anti-tumor immunity and can be used for the research of cancer and immunology^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Denikitug exhibits high on-cell affinity for human CCR8, with an average K_D of 16.8 pM^[1].
Denikitug (0.0001-100 µg/mL) specifically binds to human CCR8-expressing CHO-S cells and does not bind to human CCR4-expressing or parental CHO-S cells^[1].
Denikitug (0.001-100 µg/mL) potently antagonizes CCL1-induced signaling downstream of human CCR8^[1].
Denikitug (10^-4-100 µg/mL, overnight) mediates potent ADCC of cells expressing human CCR8, with an average EC₅₀ of 0.0067 µg/mL^[1].
Denikitug (10^-6-1000 µg/mL, overnight) potently mediates ADCC of Hut78 cells endogenously expressing human CCR8 at tumor-infiltrating Treg levels, with an average EC₅₀ of 0.0017 µg/mL and maximum killing of 67.5%^[1].
Denikitug (1 µg/mL) mediates specific depletion of tumor-infiltrating Tregs ex vivo from human ovarian, lung, and colon tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Denikitug inhibits the CCR8 receptor and has the potential to suppress tumor growth, as evidenced by the finding that antibodies against mouse CCR8 inhibit the growth of various tumors in mouse tumor models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1237  [NCBI]

P51685

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

147.2 kDa

2865822-82-6

Liquid

Colorless to light yellow

[Denikitug]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa

• 
  Flow Cytometry analysis of Raji cells labelling CCR8 (red) with Denikitug (HY-P990914). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Weaver JD, et al. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. Oncoimmunology. 2022;11(1):2141007. Published 2022 Nov 4.